Altcoin Alchemy

ETNB·NasdaqGM89bio, Inc.

$14.96+6.88 (+85.15%)·Post-Market: $14.96

Sep 18, 2025 at 23.57

Open14.98

High15.06

Low14.94

Vol80.33M

P/EN/A

Mkt cap2.22B

52W H15.06

52W L4.16

Avg Vol2.81M

Div yieldN/A

Beta1.268

EPS-3.69

89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California....

Sector: Healthcare

Industry: Biotechnology

Country: United States

Employees: 93

Website: https://www.89bio.com

See More Data from Yahoo Finance

MT Newswires - 17 hours agoTop Premarket Gainers MT Newswires - 20 hours ago89bio to be Acquired by Roche for up to $3.5 Billion in Cash, Milestone Payments; Shares Rise Pre-Bell Zacks - 13 hours agoRHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline